摘要
本研究收治Ph阳性急性淋巴细胞白血病患者3例,使用达沙替尼进行治疗,并观察患者的治疗转归情况和不良反应的发生情况。结果表明,达沙替尼在治疗Ph阳性急性淋巴细胞白血病方面有比较好的应用效果,其安全性较高。但是由于该疾病的发病人数较少,本次研究的病例数较少,随访时间较短,还需要对达沙替尼治疗Ph阳性急性淋巴细胞白血病的疗效进行更加深入的观察。
3 patients with Ph positive acute lymphoblastic leukemia were selected.We used dasatinib to treat patients,the prognosis of the patients and the occurrence of adverse reactions were observed.The results show,dasatinib has good application effects in imatinib therapy for Ph positive acute lymphoblastic leukemia,with high security.However,due to the small number of patients with this disease,the small number of cases and the short follow-up period of the disease.This still require a more in-depth observation on the efficacy of dasatinib in the treatment of Ph-positive acute lymphoblastic leukemia.
出处
《中国社区医师》
2018年第8期55-55,57,共2页
Chinese Community Doctors
